Skip to main content

Table 4 30-days survival

From: Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis

  30-days survival; n (%)
Parameter LS +
n = 82
LS -
n = 155
p-value
All patients n = 237 69/82 (84) 123/155 (79) 0.40
Subgroup: procedural categories
Isolated CABG 26/32 (81) 58/68 (85) 0.77
Isolated valve surgery / ascending aortic surgery 11/12 (92) 23/33 (70) 0.24
Combination procedures 32/38 (84) 42/54 (78) 0.64
Subgroup analysis: renal impairment
GFR >120ml/min. 32/35 (91) 50/59 (85) 0.53
GFR 85–120ml/min. 12/13 (92) 47/55 (86) 1.00
GFR 51–85 ml/min. 17/20 (85) 19/29 (66) 0.19
GFR < 51ml/min. 5/9 (56) 4/7 (57) 1.00
Dialysis 3/5 (60) 3/5 (60) 1.00
Subgroup analysis: preoperative LVEF
LVEF <25% 29/36 (81) 46/65 (71) 0.34
LVEF 25–30% 21/23 (91) 41/48 (85) 0.60
LVEF 31–35% 19/23 (83) 36/42 (86) 0.72
Subgroup analysis: EuroSCORE II
EuroSCORE II <15 37/39 (95) 84/91 (92) 0.72
EuroSCORE II 15–17 3/4 (75) 4/5 (80) 1.00
EuroSCORE II 18–20 2/2 (100) 4/5 (80) 1.00
EuroSCORE II 21–23 4/5 (80) 3/3 (100) 1.00
EuroSCORE II >23 16/23 (70) 20/39 (51) 0.19
Subgroup analysis: Recent myocardial infarction
No recent myocardial infarction 50/55 (91) 72/87 (83) 0.22
Recent myocardial infarction 19/27 (70) 51/68 (75) 0.80
  1. 30-days survival data were available for 237/246 patients (96%). Overall, 30-days survival did not differ between patients who received prophylactic LS and patients who did not. In the subgroup analyses depending on procedural categories, renal impairment, preoperative LVEF, EuroSCORE II and recent myocardial infarction, no significant differences between LS group and control group were observed
  2. Abbreviations: CABG Coronary artery bypass grafting surgery, GFR Glomerular filtration rate, LS Levosimendan, LVEF Left-ventricular ejection fraction